Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: Pretreatment determinants of response and on-treatment effect

Journal of Steroid Biochemistry and Molecular Biology

Volumn 86, Issue 3-5, 2003, Pages 301-307

  Ellis, Matthew J ^a   Rosen, Eric ^a   Dressman, Holly ^a   Marks, Jeffery ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aromatase inhibitors; Letrozole; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BIOLOGICAL MARKER; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; PARTIAL AGONIST; TAMOXIFEN; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; AMINO ACID SEQUENCE; APOPTOSIS; BREAST CARCINOMA; CANCER GROWTH; CANCER INVASION; CELL CYCLE; CLINICAL TRIAL; CONFERENCE PAPER; DNA REPLICATION; DNA SYNTHESIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SENSITIVITY; GENE EXPRESSION; GENE REPLICATION; GENETIC TRANSCRIPTION; HUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE NEU; ORGAN PRESERVATION; PREDICTION; PROSPECTIVE STUDY; PROTEIN INTERACTION; TREATMENT OUTCOME; TUMOR REGRESSION;

EID: 0242541295     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(03)00371-6     Document Type: Conference Paper

References (21)

1. Ellis M.J., Coop A., Singh B., Mauriac L., Llombert-Cussac A., Janicke F., Miller W.R., Evans D.B., Dugan M., Brady C., Quebe-Fehling E., Borgs M. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J. Clin. Oncol. 19:2001;3808-3816.
2. Eiermann W., Paepke S., Appffelstaedt J., Llombard-Cussac A., Eremin J., Vinholes J., Mauriac L., Ellis M., Lassus M., Chaudrai H.A., Dugan M., Borgs M., Semiglazov V. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann. Oncol. 12:2001;1-6.
3. Dixon J.M., Renshaw L., Bellamy C., Stuart M., Hoctin-Boes G., Miller W.R. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin. Cancer Res. 6:2000;2229-2235.
4. J.M. Dixon, T. Anderson, W.R. Miller, Phase IIb study of neoadjuvant exemestane (EXE) in locally advanced breast cancer, Proc. ASCO 20 (2001) 40b (Abstract #1908).
5. Ellis M.J. Neoadjuvant endocrine therapy for breast cancer: medical perspectives. Clin. Cancer Res. 7:2001;4388s-4391s.
6. Polychemotherapy for early breast cancer: an overview of the randomised trials, Early Breast Cancer Trialists' Collaborative Group, Lancet 352 (1998) 930-942.
7. Tamoxifen for early breast cancer: an overview of the randomised trials, Early Breast Cancer Trialists' Collaborative Group, Lancet 351 (1998) 1451-1467.
8. Fisher B., Bryant J., Wolmark N., Mamounas E., Brown A., Fisher E.R., Wickerham D.L., Begovic M., DeCillis A., Robidoux A., Margolese R.G., Cruz A.B. Jr., Hoehn J.L., Lees A.W., Dimitrov N.V., Bear H.D. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol. 16:1998;2672-2685.
9. Hutchins L.F., Unger J.M., Crowley J.J., Coltman C.A. Jr., Albain K.S. Under-representation of patients 65 years of age or older in cancer-treatment trials. N. Engl. J. Med. 341:1999;2061-2067.
10. Clark G.M., McGuire W.L., Hubay C.A., Pearson O.H., Marshall J.S. Progesterone receptors as a prognostic factor in Stage II breast cancer. N. Engl. J. Med. 309:1983;1343-1347.
11. Kastner P., Krust A., Turcotte B., Stropp U., Tora L., Gronemeyer H., Chambon P. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. 9:1990;1603-1614.
12. Wright C., Nicholson S., Angus B., Sainsbury J.R., Farndon J., Cairns J., Harris A.L., Horne C.H. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br. J. Cancer. 65:1992;118-121.
13. Berns E.M., Foekens J.A., van Staveren I.L., van Putten W.L., de Koning H.Y., Portengen H., Klijn J.G. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene. 159:1995;11-18.
14. Yamauchi H., O'Neill A., Gelman R., Carney W., Tenney D.Y., Hosch S., Hayes D.F. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J. Clin. Oncol. 15:1997;2518-2525.
15. Carlomagno C., Perrone F., Gallo C., De Laurentiis M., Lauria R., Morabito A., Pettinato G., Panico L., D'Antonio A., Bianco A.R., De Placido S. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J. Clin. Oncol. 14:1996;2702-2708.
16. M.J. Ellis, A. Coop, B. Singh, Y. Tao, A. Llombart-Cussac, F. Jänicke, L. Mauriac, E. Quebe-Fehling, H. Chaudri-Ross, D.B. Evans, W.R. Miller, Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status, Cancer Res. (2003), in press.
17. van't Veer L.J., Dal H., van de Vijver M.J., He Y.D., Hart A.A.M., Mao M., Peterse H.L., van de Kooy K., Marton M.J., Witteveen A.T., Schreber G.J., Kerkhoven R.M., Roberts C., Linsley P.S., Bernards R., Friend S.F. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:2002;530-536.
18. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Eystein Lonning P., Borresen-Dale A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 98:2001;10869-10874.
19. West M., Blanchette C., Dressman H., Huang E., Ishida S., Spang R., Zuzan H., Olson J.A. Jr., Marks J.R., Nevins J.R. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc. Natl. Acad. Sci. U.S.A. 98:2001;11462-11467.
20. M.A. Dressman, T.M. Walz, L. Barnes, S. Buchholtz, I. Kwon, C. Lavedan, M.J. Ellis, M.H., Genes that co-cluster with estrogen receptor alpha in microarray analysis of breast biopsies, Pharmacogenom. J. 1 (2001) 135-141.
21. Shipp M.A., Ross K.N., Tamayo P., Weng A.P., Kutok J.L., Aguiar R.C., Gaasenbeek M., Angelo M., Reich M., Pinkus G.S., Ray T.S., Koval M.A., Last K.W., Norton A., Lister T.A., Mesirov J., Neuberg D.S., Lander E.S., Aster J.C., Golub T.R. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med. 8:2002;68-74.